EyePoint Pharmaceuticals ... (EYPT)
NASDAQ: EYPT
· Real-Time Price · USD
8.94
0.69 (8.36%)
At close: Jun 06, 2025, 3:59 PM
8.60
-3.75%
After-hours: Jun 06, 2025, 04:49 PM EDT
8.36% (1D)
| Bid | 6.4 |
| Market Cap | 614.83M |
| Revenue (ttm) | 56.04M |
| Net Income (ttm) | -146.78M |
| EPS (ttm) | -2.42 |
| PE Ratio (ttm) | -3.69 |
| Forward PE | -2.82 |
| Analyst | Buy |
| Ask | 10.7 |
| Volume | 828,812 |
| Avg. Volume (20D) | 831,603 |
| Open | 7.49 |
| Previous Close | 8.25 |
| Day's Range | 8.34 - 9.09 |
| 52-Week Range | 3.91 - 13.99 |
| Beta | 1.64 |
About EYPT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EYPT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EYPT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+18.12%
EyePoint shares are trading higher after the compa...
Unlock content with
Pro Subscription
4 months ago
+2.36%
EyePoint Pharmaceuticals shares are trading higher after the company announced six-month results for its Phase 2 VERONA trial and stated the trial met its primary endpoint.
1 month ago · seekingalpha.com
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call TranscriptEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker ...
